LUMC and Ixaka announce collaboration to advance cell therapy development

The Leiden University Medical Center (LUMC) and Ixaka Ltd. have announced a research collaboration on 30 March 2021, to better understand REX-001, Ixaka’s lead cell therapy product. The project will be led by Professor Paul Quax, Head of Experimental Vascular Surgery at the LUMC, to support accelerated development of REX-001 in Phase III clinical trials for the treatment of chronic limb-threatening ischemia (CLTI).

CLTI is a life-threatening vascular disease caused by a build-up of fatty deposits in the arteries, which limits the adequate flow of blood and oxygen to a specific part of the body, such as the leg muscles. According to Quax: “there are not many available options to treat the disease as it progresses and the current procedures to manage symptoms of CLTI at advanced stages are often unsuitable or ineffective”. For example, cutting-edge methods such as the use of minimally-invasive catheters and surgical reconstruction do not help in restoring blood flow or preventing major amputations. “This has created a critical need for new and innovative therapies”, highlights Quax.

Read the full article